Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Based Regimens

Inclusion criteria

* Histologically or cytologically confirmed renal carcinoma * CT-confirmed metastatic sites * Must have measurable disease, defined as ≥ 1 unidimensionally measurable lesion measured as ≥ 20 mm with conventional techniques OR as ≥ 10 mm with spiral CT scan * Disease progression after IL-2 * Age 18 or older * ECOG performance status 1-3 * Life expectancy ≥ 2 months * WBC ≥ 3,000/mm3 * Platelet count ≥ 100,000/mm3 * Hemoglobin ≥ 7.5 g/dL * Creatinine ≤ 1.5 mg/dL (2.0 mg/dL in post-nephrectomy patients) * Total bilirubin ≤ 1.5 mg/dL * AST ≤ 3.0 times normal * Alkaline phosphatase ≤ 2.5 times normal (10 times ULN in presence of bone metastases) * Not pregnant or nursing * No history of autoimmune * No history of serious cardiac arrhythmia, congestive heart failure, angina pectoris, or other severe cardiovascular disease (i.e., New York Heart Association class III or IV) * No CNS metastases by neurologic exam and/or MRI * No history of seizure disorders * No local and/or systemic infections requiring antibiotics within 28 days prior to study entry * No other malignancy * Written informed consent